TELIX QSAM INC.
qsambio.comQSAM Biosciences, Inc. engages in the provision of nuclear medicines for the treatment of cancer and related diseases and conditions. The company is headquartered in Austin, Texas and currently employs 4 full-time employees. The company went IPO on 2011-08-25. The Company’s technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC. Iso Therapeutics Group LLC is also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 and the chelant DOTMP (1,4,7,10-tetraazacyclododecanetetramethylene-phosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to locate the anatomical distribution. Its subsidiary is QSAM Therapeutics Inc.
Financial snapshot data is not available right now.
Loading...
